AACR Annual Meeting 2022: Showcasing our Precision Therapy Pipeline

Posted on April 8, 2022

At the American Association for Cancer Research (AACR) Annual Meeting 2022, we’re presenting new clinical and preclinical data for multiple programs across our precision therapy portfolio, highlighting our goal to bring the promise of precision medicine to broad patient populations with genomically defined cancers, including lung, ovarian and breast cancers.

Hear more from our scientific and clinical development experts:


Fouad Namouni, M.D., President of Research & Development

Brenton Mar, M.D., Ph.D., Vice President of Clinical Development, and Chiara Conti, Ph.D., Director of Biology, on our programs for EGFR-mutant non-small cell lung cancer

Maria Roche, Vice President of Clinical Development, and Victoria Brown, Senior Scientist in Biology, on our program for cyclin E aberrant cancers

More posts and webinars